Back to Top Skip to main content Skip to sub-navigation

Army conducts commercial aircraft decontamination efficacy test

Man wearing mask, looking at ceiling of an airplane Commercial Aircraft Decontamination Efficacy Test conducted November 2020 to March 2021 at Dugway Proving Ground. The test determined if current means of neutralizing the SARS-C0V-2 virus in a passenger jet, which causes the disease COVID-19, are effective, and to possibly find even better methods. (Photo by Albert Vogel, Army Dugway Proving Grounds.)

Recommended Content:

Coronavirus

The BioTesting Division (BTD) at the U.S. Army Dugway Proving Ground in Utah will soon start a study to determine how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is transmitted among airline passengers. The efficacy of practices to decontaminate the virus that causes COVID-19 will also be studied.

A section of a jet airliner fuselage, containing three rows of seats, five windows, overhead storage bins, armrests and folding seat-back trays was trucked to Dugway Proving Ground for the test. Outside air will pass through the fuselage’s intact ventilation system, to study interior airflow and how the virus is disseminated.

SARS-CoV-2, which causes the COVID-19 disease, will be used only in industrially filtered and sealed labs at BTD. MS2, a virus that infects E. coli bacteria but is harmless to humans, will simulate SARS-CoV-2 outside the labs as required. The test will be conducted from mid-November through March 2021.

“MS2 has been used a lot in these kind of decontamination studies,” said a BTD Test Officer Angelo Madonna, which resides on DPG, but it is a tenant unit under the command of the U.S. Army Combat Capabilities Development Command’s Chemical Biological Center.

Two commercial sprayers and two commercial liquid disinfectants will be tried in different combinations on surfaces in the passenger area to gauge effectiveness.

“They also want to know if the virus can be disinfected when it’s airborne,” Madonna said.

Part of this trial includes a machine that replicates the release of particles by human coughing, sneezing and speaking and is combined with artificial saliva developed in the lab.

A variety of trials will explore, using the MS2 simulant, how SARS-CoV-2 travels within a commercial airliner’s fuselage. The most practical and effective means to decontaminate, hoping to make airline travel safer without long delays and setup, will also be examined. This includes ultraviolet light’s effectiveness against aerosolized viruses.

Also, samples of fabric and plastic taken from the fuselage will be contaminated in the filtered lab with the MS2 virus, then disinfected with current equipment and methods.

Ultimately, the varied testing conducted at BTD is expected to advance our understanding of the transmission and decontamination of SARS-CoV-2, which has infected more than 47 million people worldwide with the COVID-19 disease.

You also may be interested in...

DHA-PI 6205.01: Medical Logistics Guidance for the DoD Coronavirus Disease 2019 (COVID-19) Vaccination Program

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (n), establishes the Defense Health Agency's (DHA's) procedures for ordering, receiving, and managing COVID-19 Vaccines inventory and ancillary kits.

DHA-IPM 20-004: Department of Defense (DoD) Coronavirus Disease 2019 (COVID-19) Vaccination Program Implementation

Policy

This Defense Health Agency (DHA) Interim Procedures Memorandum (IPM), based on the authority of References (a) through (d), and in accordance with the guidance cited in References (e) through (aa), establishes the DHA’s procedures to implement instructions, assign responsibilities, and prescribe procedures for the COVID-19 Vaccination Program. This DHA-IPM applies to DHA, DHA Components (activities under the authority direction, and control of the DHA), Military Departments (MILDEP), and the United States Coast Guard (CG). This DHA-IPM cancels and replaces DHA-IPM 20-004, “Department of Defense (DoD) Coronavirus Disease 2019 (COVID-19) Vaccination Program Implementation,” December 13, 2020.

TAB A MEO COVID19 Medical Coding Policy

Policy

Memorandum for DHA Staff - Military Medical Treatment Facilities to Implement Updated DHA COVID-19 Medical Coding Policy

  • Identification #: N/A
  • Date: 3/25/2021
  • Type: Memorandums
  • Topics: Coronavirus

DHA COVID19 Medical Coding PolicyV5 1v

Policy

Establishes the DHA procedures to standardize the coding for Coronavirus 2019 (COVID-19) within military medical treatment facilities (MTFs). This memorandum replaces DHA-Policy Memorandum 20-003 of July 1, 2020. Attachment 1 was updated to include the 2021 procedure and diagnosis codes for COVID-19, including the new vaccination and treatment codes.

  • Identification #: 20-003
  • Date: 3/25/2021
  • Type: Memorandums
  • Topics: Coronavirus

Supplemental Guidance for Providing DoD Coronavirus Disease 2019 Vaccines to DoD Contractor Employees and Select Foreign Nationals

Policy

This memorandum provides supplemental guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines, in accordance with reference (a). The Defense Health Agency (DHA) is the lead coordinating DoD Component for executing this guidance, in coordination with the Military Departments and other DoD Components as appropriate.

HA Guidance for Coronavirus Disease 2019 (COVID-19) Laboratory Pre-Testing Questionnaire

Policy

This memorandum provides guidance for a COVID-19 laboratory pre-testing questionnaire that will be mandatory for all Active Duty Service members and encouraged for all other DoD beneficiaries treated at military medical treatment facilities.

Executive Order on Ensuring Access to United States Government COVID-19 Vaccines

Policy

This EO outlines who should receive priority access to COVID-19 vaccines developed in the United States or procured by the United States Government (“United States Government COVID-19 Vaccines”).

Coronavirus Disease 2019 Vaccine Guidance

Policy

This memorandum provides guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines. The Defense Health Agency (DHA) is the lead coordinating DoD Component for executing this guidance, in coordination with the Military Departments and other DoD Components.

DHA-AI 3020-01: Return to the Workplace Staffing Plan in the Coronavirus Disease 2019 Environment

Policy

This Defense Health Agency-Administrative Instruction (DHA-AI), based on the authority of References (a) through (b) and in accordance with the guidance of References (c) through (z3), establishes the Defense Health Agency's (DHA) plan to return to full operations and support the whole-of-government response, during the Coronavirus Disease 2019 (COVID-19) pandemic. This DHA-AI also provides a preventive plan to monitor and assess for the appearance of new cases and implement those processes that will prevent them from impacting the workforce. The processes describe herein are intended to offer an actionable plan for the workforce to re-enter DHA Administrative Offices. See Appendix 1 for a summary of the DHA Administrative Office Reopening Plan. The plan uses the Force Health Protection Guidance and Health Protection Conditions (HPCON), in accordance with Reference (d), to ensure protection for the workforce, including the most vulnerable-to-serious complications from the virus while enabling DHA Administrative Offices to continue its mission. See Appendix 2 for the conceptual HPCON framework.

  • Identification #: 3020-01
  • Date: 11/3/2020
  • Type: Administrative Instructions
  • Topics: Coronavirus

DHA AI 3020.01: Return to the Workplace Staffing Plan in the Coronavirus Disease 2019 (COVID-19) Environment

Policy

This Defense Health Agency-Administrative Instruction (DHA-AI), establishes the Defense Health Agency’s (DHA) plan to return to full operations and support the whole-of-government response, during the Coronavirus Disease 2019 (COVID-19) pandemic and in preparation for regression or resurgence in COVID-19 cases that could impact the workforce.

  • Identification #: DHA AI 3020.01
  • Date: 6/12/2020
  • Type: Administrative Instructions
  • Topics: Coronavirus
Showing results 1 - 10 Page 1 of 1

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.